CL2014002269A1 - Método para predecir sensibilidad de crecimiento celular tumoral a un inhibidor de wnt por medio de determinación de estado de mutación de región cromosómica rnf43; kit; composición farmacéutica que comprende inhibidor de wnt útil para tratar cáncer de pancreas. - Google Patents

Método para predecir sensibilidad de crecimiento celular tumoral a un inhibidor de wnt por medio de determinación de estado de mutación de región cromosómica rnf43; kit; composición farmacéutica que comprende inhibidor de wnt útil para tratar cáncer de pancreas.

Info

Publication number
CL2014002269A1
CL2014002269A1 CL2014002269A CL2014002269A CL2014002269A1 CL 2014002269 A1 CL2014002269 A1 CL 2014002269A1 CL 2014002269 A CL2014002269 A CL 2014002269A CL 2014002269 A CL2014002269 A CL 2014002269A CL 2014002269 A1 CL2014002269 A1 CL 2014002269A1
Authority
CL
Chile
Prior art keywords
wnt inhibitor
kit
pharmaceutical composition
cell growth
tumor cell
Prior art date
Application number
CL2014002269A
Other languages
English (en)
Inventor
Feng Cong
Huaixiang Hao
Hsin-I Hsieh
Xiaomo Jiang
Jun Liu
Nicholas Ng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47790546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002269(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2014002269A1 publication Critical patent/CL2014002269A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2014002269A 2012-02-28 2014-08-27 Método para predecir sensibilidad de crecimiento celular tumoral a un inhibidor de wnt por medio de determinación de estado de mutación de región cromosómica rnf43; kit; composición farmacéutica que comprende inhibidor de wnt útil para tratar cáncer de pancreas. CL2014002269A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261604290P 2012-02-28 2012-02-28

Publications (1)

Publication Number Publication Date
CL2014002269A1 true CL2014002269A1 (es) 2014-12-19

Family

ID=47790546

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002269A CL2014002269A1 (es) 2012-02-28 2014-08-27 Método para predecir sensibilidad de crecimiento celular tumoral a un inhibidor de wnt por medio de determinación de estado de mutación de región cromosómica rnf43; kit; composición farmacéutica que comprende inhibidor de wnt útil para tratar cáncer de pancreas.

Country Status (19)

Country Link
US (3) US20150125857A1 (es)
EP (2) EP2820151B1 (es)
JP (2) JP6397335B2 (es)
KR (1) KR20140132712A (es)
CN (1) CN104302782A (es)
AU (1) AU2013226323B2 (es)
BR (1) BR112014020233A2 (es)
CA (1) CA2864306A1 (es)
CL (1) CL2014002269A1 (es)
ES (2) ES2797533T3 (es)
IL (1) IL233920A0 (es)
MX (1) MX2014010265A (es)
NZ (1) NZ627864A (es)
PH (1) PH12014501930A1 (es)
RU (2) RU2636000C2 (es)
SG (1) SG11201404492VA (es)
TN (1) TN2014000337A1 (es)
WO (1) WO2013130364A1 (es)
ZA (1) ZA201405553B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3281640A1 (en) 2011-06-17 2018-02-14 President and Fellows of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
WO2013054307A2 (en) 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
ES2797533T3 (es) 2012-02-28 2020-12-02 Novartis Ag Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43
CN105142641A (zh) 2013-03-12 2015-12-09 广州源生医药科技有限公司 用于治疗癌症的化合物
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
CN106714831A (zh) * 2014-04-21 2017-05-24 艾伯维施特姆森特克斯有限责任公司 新的抗‑rnf43抗体和使用方法
KR102525131B1 (ko) * 2014-10-08 2023-04-24 레드엑스 파마 피엘씨 Wnt 신호 경로의 억제제로서의 N-피리디닐 아세트아미드 유도체
US20160312207A1 (en) * 2015-04-21 2016-10-27 The Board Of Trustees Of The Leland Stanford Junior University R-spondin antagonists and methods of treating cancer associated with aberrant activation of wnt signaling
AU2016267142B2 (en) * 2015-05-26 2020-12-24 Curegenix Corporation Tumor biomarkers and use thereof
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
WO2019245460A1 (en) * 2018-06-21 2019-12-26 National University Of Singapore Stratifying cancer patients harbouring oncogenic mutations in the e3 ubiquitin ligase rnf43
CA3104868A1 (en) 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
US20210299233A1 (en) * 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
US12534762B2 (en) 2018-09-28 2026-01-27 Children's Medical Center Corporation Treating atopic dermatitis by targeting the WNT pathway
CA3141632A1 (en) 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors
CN113564249B (zh) * 2020-04-28 2023-06-16 中国科学院分子细胞科学卓越创新中心 CXorf67在判断肿瘤对DNA损伤药物的敏感性中的应用
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング, インコーポレイテッド 肝臓特異的Wntシグナル増強分子およびその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
EP1513934B1 (en) * 2002-06-06 2011-03-02 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
ES2361541T3 (es) * 2002-06-06 2011-06-17 Oncotherapy Science, Inc. Genes y polipéptidos relacionados con cánceres de colon humanos.
WO2004032838A2 (en) * 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
US7718364B2 (en) 2003-03-25 2010-05-18 John Wayne Cancer Institute DNA markers for management of cancer
RU2007104925A (ru) * 2004-07-09 2008-08-20 Те Риджентс Оф Те Юниверсити Оф Калифорния (Us) СПОСОБЫ ЛЕЧЕНИЯ РАКА С ПРИМЕНЕНИЕМ АГЕНТОВ, КОТОРЫЕ ИНГИБИРУЮТ СИГНАЛЬНЫЙ ПУТЬ Wnt16
NZ555216A (en) * 2004-11-10 2010-05-28 Hubrecht Lab Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
CA2601157A1 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2011004379A1 (en) * 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
EP2549399A1 (en) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
WO2013054307A2 (en) 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
ES2797533T3 (es) 2012-02-28 2020-12-02 Novartis Ag Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43
UA122079C2 (uk) 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6

Also Published As

Publication number Publication date
JP6397335B2 (ja) 2018-09-26
SG11201404492VA (en) 2014-10-30
ES2797533T3 (es) 2020-12-02
ZA201405553B (en) 2015-12-23
CN104302782A (zh) 2015-01-21
EP3693476B1 (en) 2023-10-18
ES2968742T3 (es) 2024-05-13
EP2820151A1 (en) 2015-01-07
JP2015511484A (ja) 2015-04-20
EP2820151B1 (en) 2020-03-25
KR20140132712A (ko) 2014-11-18
IL233920A0 (en) 2014-09-30
TN2014000337A1 (en) 2015-12-21
AU2013226323A1 (en) 2014-09-11
BR112014020233A2 (pt) 2017-07-04
RU2017120287A (ru) 2018-11-15
HK1199744A1 (en) 2015-07-17
US20150125857A1 (en) 2015-05-07
JP2018172408A (ja) 2018-11-08
US20170306409A1 (en) 2017-10-26
AU2013226323B2 (en) 2016-07-14
US20190203301A1 (en) 2019-07-04
CA2864306A1 (en) 2013-09-06
WO2013130364A1 (en) 2013-09-06
PH12014501930A1 (en) 2014-11-24
NZ627864A (en) 2015-12-24
EP3693476A1 (en) 2020-08-12
MX2014010265A (es) 2015-06-23
RU2636000C2 (ru) 2017-11-17
RU2014139044A (ru) 2016-04-20

Similar Documents

Publication Publication Date Title
CL2014002269A1 (es) Método para predecir sensibilidad de crecimiento celular tumoral a un inhibidor de wnt por medio de determinación de estado de mutación de región cromosómica rnf43; kit; composición farmacéutica que comprende inhibidor de wnt útil para tratar cáncer de pancreas.
BR112014002616A2 (pt) método para detectar cãncer pancreático e reagente ou kit para detectar câncer pancreático
IL276488A (en) Method of predicting breast cancer prognosis
EP4219765C0 (en) PROGNOSIS OF PROSTATE CANCER USING BIOMARKERS
DK2753334T3 (da) Fap-aktiverede proteasomhæmmere til behandling af solide tumorer
HUE057264T2 (hu) Eljárás új IDH1 inhibitorok elõállítására
GB2487632B (en) Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
HRP20181779T1 (hr) Spojevi i postupci za modulaciju kinaze, te indikacije za njih
WO2012106718A3 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
PT3581654T (pt) Métodos e composições para a inibição específica de glicolato oxidase (hao1) por rna de cadeia dupla
IL231813B (en) Use of preparations containing ATR inhibitors for the treatment of pancreatic cancer and non-small cell lung cancer
CO6761389A2 (es) Inhibidores de nampt y rock
SI2697185T1 (sl) Postopki za proizvodnjo visokoogljičnih biogenih reagentov
DK3147373T3 (da) Fremgangsmåde til anvendelse af genekspression til at bestemme prognosen for prostatacancer
GT201300078A (es) Proceso para la preparacion de inhibidores de pan-cdk de la formula ( i ), e intermediarios de la preparacion
PL2643698T3 (pl) Biomarkery do przewidywania skuteczności immunoterapii raka
WO2014055543A3 (en) Biomarkers and methods to predict response to inhibitors and uses thereof
EP2831281A4 (en) MOLECULAR MARKERS FOR THE PROGNOSTIC PREDICTION OF PROSTATE CANCER, METHOD AND KIT THEREFOR
BR112014000443A2 (pt) métodos e ácidos nucléicos para determinação do prognóstico de um indivíduo com câncer
IL253710B (en) Biomarkers for pancreatic cancer and kits and methods for detecting same
CL2015000192A1 (es) Método de seleccion de un sujeto que padece un tumor maligno para tratamiento con inhibidor de jak/stat que comprende determinar nivel de expresión de biomarcadores.
MX2013014622A (es) Enfermedad tromboembolica.
DK2452189T3 (da) Fremgangsmåde til identifikation af forbindelser til behandling af cancer
IL229132B (en) Detection of target nucleic acid sequences by po cleavage and hybridization